Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

KY61559X1045
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00XQZQTS9
MLTX
MoonLake Immunotherapeutics
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
MoonLake Immunotherapeutics
ISIN
KY61559X1045
TICKER
MLTX
MIC
XNAS
REUTERS
MLTX.OQ
BLOOMBERG
MLTX US
Tue, 18.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 18, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 18, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.11.2025       Moonlake Immunotherapeutics
KY61559X1045

MLTX Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, Nov. 18, 2025 /PRNewswire/ -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial r...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.11.2025       Moonlake Immunotherapeutics
KY61559X1045

BENSALEM, Pa., Nov. 18, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX). I...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 18, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177904&wire=5&...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plainti...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.11.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 17.11.2025       Moonlake Immunotherapeutics
KY61559X1045

PHILADELPHIA, Nov. 17, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholder...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177687&wire=5&...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 16.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 16, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 15.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 14, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.SO WH...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 14, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177495&wire=5&...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.11.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Nov. 14, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX)....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.11.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in MoonLake between March 10, 2024 and Septem...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 14, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 13.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 13, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.11.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.11.2025       Moonlake Immunotherapeutics
KY61559X1045

San Francisco, California--(Newsfile Corp. - November 13, 2025) - A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or "SLK"), its highly anticipated tre...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 12, 2025 /PRNewswire/ -- Why: New York, N.Y., November 12, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of common s...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 12, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177026&wire=5&...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 12, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 12, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.11.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you suffered losses in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson dir...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.11.2025       Moonlake Immunotherapeutics
KY61559X1045

San Diego, California--(Newsfile Corp. - November 11, 2025) - Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Peters v. MoonLake Immunotherapeutics, No. 25-cv-08612 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and char...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 11, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=176752&wire=5&...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.11.2025       Moonlake Immunotherapeutics
KY61559X1045

SAN FRANCISCO, Nov. 11, 2025 /PRNewswire/ -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or "SLK"), its highly...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.11.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Nov. 11, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.11.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 10, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 10, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=176446&wire=5&...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 10, 2025  The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 10, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 08.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 8, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are e...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 08.11.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in MoonLake between March 10, 2024 and Septem...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 08.11.2025       Moonlake Immunotherapeutics
KY61559X1045

SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Peters v. MoonLake Immunotherapeutics, No. 25-cv-08612 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) com...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 08.11.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Nov. 7, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) have opportunity to lead the securities fraud class action lawsuit....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 08.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 7, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.11.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Nov. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.11.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Nov. 7, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  MoonLake Immunotherapeutics ("MoonLake " or "the Company") (NASDAQ: MLTX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S....
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.11.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - November 6, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.SO WHA...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.11.2025       Moonlake Immunotherapeutics
KY61559X1045

MLTX Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 tri...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.11.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. (“MoonLake” or the “Company”) (NASDAQ: MLTX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.11.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Nov. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders...
Read more
Moonlake Immunotherapeutics
Technical Analysis Termsheets Terminal
Permalink